Increased risk of COVID-19-related admissions in patients with active solid organ cancer in the West Midlands region of the UK: a retrospective cohort study.
dc.contributor.author | Akingboye, Akinfemi | |
dc.contributor.author | Mahmood, Fahad | |
dc.contributor.author | Amiruddin, Nabeel | |
dc.contributor.author | Reay, Michael | |
dc.contributor.author | Nightingale, Peter | |
dc.contributor.author | Ogunwobi, Olorunseun O | |
dc.date.accessioned | 2024-06-18T13:19:52Z | |
dc.date.available | 2024-06-18T13:19:52Z | |
dc.date.issued | 2021-12-13 | |
dc.identifier.citation | Akingboye A, Mahmood F, Amiruddin N, Reay M, Nightingale P, Ogunwobi OO. Increased risk of COVID-19-related admissions in patients with active solid organ cancer in the West Midlands region of the UK: a retrospective cohort study. BMJ Open. 2021 Dec 13;11(12):e053352. doi: 10.1136/bmjopen-2021-053352 | en_US |
dc.identifier.eissn | 2044-6055 | |
dc.identifier.doi | 10.1136/bmjopen-2021-053352 | |
dc.identifier.pmid | 34903546 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14200/4895 | |
dc.description.abstract | Objective: Susceptibility of patients with cancer to COVID-19 pneumonitis has been variable. We aim to quantify the risk of hospitalisation in patients with active cancer and use a machine learning algorithm (MLA) and traditional statistics to predict clinical outcomes and mortality. Design: Retrospective cohort study. Setting: A single UK district general hospital. Participants: Data on total hospital admissions between March 2018 and June 2020, all active cancer diagnoses between March 2019 and June 2020 and clinical parameters of COVID-19-positive admissions between March 2020 and June 2020 were collected. 526 COVID-19 admissions without an active cancer diagnosis were compared with 87 COVID-19 admissions with an active cancer diagnosis. Primary and secondary outcome measures: 30-day and 90-day post-COVID-19 survival. Results: In total, 613 patients were enrolled with male to female ratio of 1:6 and median age of 77 years. The estimated infection rate of COVID-19 was 87 of 22 729 (0.4%) in the patients with cancer and 526 of 404 379 (0.1%) in the population without cancer (OR of being hospitalised with COVID-19 if having cancer is 2.942671 (95% CI: 2.344522 to 3.693425); p<0.001). Survival was reduced in patients with cancer with COVID-19 at 90 days. R-Studio software determined the association between cancer status, COVID-19 and 90-day survival against variables using MLA. Multivariate analysis showed increases in age (OR 1.039 (95% CI: 1.020 to 1.057), p<0.001), urea (OR 1.005 (95% CI: 1.002 to 1.007), p<0.001) and C reactive protein (CRP) (OR 1.065 (95% CI: 1.016 to 1.116), p<0.008) are associated with greater 30-day and 90-day mortality. The MLA model examined the contribution of predictive variables for 90-day survival (area under the curve: 0.749); with transplant patients, age, male gender and diabetes mellitus being predictors of greater mortality. Conclusions: Active cancer diagnosis has a threefold increase in risk of hospitalisation with COVID-19. Increased age, urea and CRP predict mortality in patients with cancer. MLA complements traditional statistical analysis in identifying prognostic variables for outcomes of COVID-19 infection in patients with cancer. This study provides proof of concept for MLA in risk prediction for COVID-19 in patients with cancer and should inform a redesign of cancer services to ensure safe delivery of cancer care. | en_US |
dc.language.iso | en | en_US |
dc.publisher | BMJ Publishing Group | en_US |
dc.relation.url | http://bmjopen.bmj.com/ | en_US |
dc.rights | © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | |
dc.subject | Oncology. Pathology. | en_US |
dc.title | Increased risk of COVID-19-related admissions in patients with active solid organ cancer in the West Midlands region of the UK: a retrospective cohort study. | en_US |
dc.type | Article | en_US |
dc.type | Other | en_US |
dc.source.journaltitle | BMJ Open | en_US |
dc.source.volume | 11 | |
dc.source.issue | 12 | |
dc.source.beginpage | e053352 | |
dc.source.endpage | ||
dc.source.country | United States | |
dc.source.country | England | |
rioxxterms.version | NA | en_US |
oa.grant.openaccess | na | en_US |